--- title: "LifeMD Pref Share LFMDP 8.875 Perp 10/15/22 | 8-K: FY2026 Q2 Revenue: USD 47.28 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295008583.md" datetime: "2026-08-05T20:16:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295008583.md) - [en](https://longbridge.com/en/news/295008583.md) - [zh-HK](https://longbridge.com/zh-HK/news/295008583.md) generator: "portal-rs" --- # LifeMD Pref Share LFMDP 8.875 Perp 10/15/22 | 8-K: FY2026 Q2 Revenue: USD 47.28 M Revenue: As of FY2026 Q2, the actual value is USD 47.28 M. EPS: As of FY2026 Q2, the actual value is USD -0.16. EBIT: As of FY2026 Q2, the actual value is USD -7.084 M. #### Total Revenue LifeMD reported total revenue of $47.3 million for the second quarter of 2026, reflecting a -4% year-over-year change compared to $49.0 million in the prior-year period. Approximately 84% of this revenue was derived from recurring subscriptions. #### Gross Profit and Margin Gross profit for the quarter was $42.0 million, remaining essentially flat compared to the prior-year period. Gross margin expanded to approximately 89%, an increase of approximately 280 basis points from 86% in the prior-year period, primarily due to lower shipping and fulfillment costs and the scaling of the Company’s affiliated pharmacy. #### Operating Expenses Selling and Marketing Expenses increased 27% year-over-year to $28.0 million but declined $1.8 million from the first quarter of 2026, consistent with planned reductions in patient acquisition spending. General and Administrative Expenses declined 5% to $13.6 million, driven by lower employee expenses and legal and professional services fees. #### Operating Loss from Continuing Operations The operating loss from continuing operations was - $7.1 million, compared to - $2.3 million in the prior-year period. #### Net Loss GAAP net loss from continuing operations attributable to common stockholders was - $7.9 million, or - $0.16 per share, compared with a GAAP net loss of - $3.8 million, or - $0.09 per share, in the prior-year period. #### Adjusted EBITDA The adjusted EBITDA loss was approximately - $3.5 million, compared with an adjusted EBITDA of approximately $3.9 million in the prior-year period, representing a -191% year-over-year change. #### Cash and Liquidity LifeMD exited the quarter with $25.1 million in cash and no debt, with an undrawn $30 million revolving credit facility, enhancing its financial flexibility. #### Operational Metrics Total active subscribers increased 20% year-over-year to approximately 356,000 at quarter end. Subscribers to the Weight Management Program grew to approximately 108,000 at quarter end, up from just under 100,000 at the end of the first quarter of 2026. Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies, marking the effective end of the transition away from compounded GLP-1 medications. Operating trends in Women’s Health continue to improve, with lower customer acquisition costs and a broad set of new pharmacy products launching in the second half of the year. LifeMD launched an exclusive telehealth co-marketing collaboration with Halozyme’s wholly-owned subsidiary, Antares Pharma, Inc., for XYOSTED®, and additional strategic partnerships and enterprise relationships are advancing toward execution in the second half of 2026. #### Outlook and Guidance LifeMD expects a return to positive adjusted EBITDA in the second half of 2026 and anticipates an annualized exit revenue run rate of approximately $250 million with approximately $22 million of annualized adjusted EBITDA by the fourth quarter of 2026. For the third quarter of 2026, the Company projects revenue between $48 million and $51 million, and adjusted EBITDA in the range of - $1 million to positive $2 million. The full-year 2026 guidance has been revised to revenue of $205.5 million to $212.5 million and adjusted EBITDA in the range of - $6.0 million to breakeven, including $2 million to $3 million of net launch costs for XYOSTED®. ### Related Stocks - [LFMDP.US](https://longbridge.com/en/quote/LFMDP.US.md) ## Related News & Research - [SYNSAM: Double-digit sales and profit growth in Q2, with strong margins and expanding subscriptions](https://longbridge.com/en/news/296571574.md) - [XPLRA: Subscription growth and margin expansion drive improved profitability despite flat revenue](https://longbridge.com/en/news/296303980.md) - [OpenAI Codex lead points to sub2api as users report shrinking limits](https://longbridge.com/en/news/296611126.md) - [eDreams Odigeo scales Prime travel subscription platform in Poland](https://longbridge.com/en/news/296765244.md) - [eDreams ODIGEO Advances Its International Expansion With the Scaling of Its Prime Subscription Platform in Poland | EDDRF Stock News](https://longbridge.com/en/news/296766020.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**